| scholarly article | Q13442814 |
| P2093 | author name string | Arif Hussain | |
| Kai Sun | |||
| C Daniel Mullins | |||
| Eberechukwu Onukwugha | |||
| Abdalla Aly | |||
| Husam Albarmawi | |||
| P2860 | cites work | Metastatic bone disease: clinical features, pathophysiology and treatment strategies | Q28202792 |
| A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | Q34152748 | ||
| Clinical features of metastatic bone disease and risk of skeletal morbidity | Q34576366 | ||
| Physician visits prior to treatment for clinically localized prostate cancer. | Q34610617 | ||
| Emerging Therapeutic for the Treatment of Skeletal-related Events Associated With Metastatic Castrate-resistant Prostate Cancer. | Q34661684 | ||
| Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods | Q35749531 | ||
| Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer | Q35878821 | ||
| Physician preferences for bone metastasis drug therapy in Canada | Q36169862 | ||
| Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer | Q36578762 | ||
| The cost of treating skeletal-related events in patients with prostate cancer. | Q37159483 | ||
| Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis | Q37430019 | ||
| Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). | Q37673201 | ||
| Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System | Q37888901 | ||
| Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. | Q38195720 | ||
| Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial. | Q38396913 | ||
| Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancer. | Q38775761 | ||
| Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer | Q38777682 | ||
| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study | Q41904942 | ||
| A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). | Q44571738 | ||
| The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. | Q44884003 | ||
| Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer | Q44918129 | ||
| The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer | Q45285286 | ||
| Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). | Q45934103 | ||
| Skeletal fractures negatively correlate with overall survival in men with prostate cancer | Q74628779 | ||
| Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer | Q79687150 | ||
| Pathologic fractures correlate with reduced survival in patients with malignant bone disease | Q80974012 | ||
| Payer Costs for Inpatient Treatment of Pathologic Fracture, Surgery to Bone, and Spinal Cord Compression Among Patients with Multiple Myeloma or Bone Metastasis Secondary to Prostate or Breast Cancer | Q82410739 | ||
| The Delivery of Prostate Cancer Care in the United States: Implications for Delivery System Reform | Q85205694 | ||
| Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases | Q85419125 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 340.e23-340.e31 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | Urologic Oncology | Q2113446 |
| P1476 | title | Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis | |
| P478 | volume | 36 |
Search more.